Quince Therapeutics Reports $83.98 Million Net Loss and Explores Strategic Alternatives

Quince Therapeutics, Inc. reported significant financial challenges in its recent 10-K filing for the fiscal year ending December 31, 2025. The company recorded a net loss of $83.98 million, a 48% increase from the previous year's loss of $56.83 million. This increase in losses was primarily attributed to heightened research and development expenses, which surged by 90% to $35.38 million, largely due to costs associated with the failed Phase 3 NEAT clinical trial for its lead drug candidate, eDSP. The trial did not meet its primary or secondary endpoints, leading to the decision to discontinue further development of eDSP.

In terms of operational changes, Quince Therapeutics has engaged LifeSci Capital as its exclusive financial advisor to explore strategic alternatives, including a potential reverse merger. The company has no current product candidates and is focused on preserving cash while evaluating these options. As of December 31, 2025, Quince had cash, cash equivalents, and short-term investments totaling $17.8 million, which it anticipates will not be sufficient to fund operations for the next twelve months without additional financing. The company has indicated plans to raise funds through public offerings or private financing, although there is no guarantee of success.

The company’s total operating expenses for 2025 were $58.07 million, slightly up from $57.29 million in 2024. This increase was driven by a fair value adjustment for contingent consideration related to the EryDel acquisition, which amounted to $7.64 million. Additionally, Quince reported a significant fair value adjustment for warrants of $21.47 million, reflecting the volatility in its stock price. The company’s accumulated deficit reached $460.45 million by the end of 2025, underscoring its ongoing financial struggles.

Quince Therapeutics has also seen changes in its workforce, with a total employee count of 38 as of December 31, 2025, down from previous levels as the company undertook cost-cutting measures. The company is currently evaluating its strategic direction and may consider asset sales, although it does not expect to receive meaningful consideration from such transactions. The outlook remains uncertain, with substantial doubt about the company's ability to continue as a going concern without securing additional funding.

Looking ahead, Quince Therapeutics is focused on restructuring and exploring strategic alternatives to maximize shareholder value. The company has indicated that it may pursue a reverse merger or other financing options to stabilize its financial position. However, the lack of current product candidates and the unsuccessful clinical trial results present significant hurdles to achieving a turnaround.